Economic and Clinical Benefits of Bivalent Respiratory Syncytial Virus Prefusion F (RSVpreF) Maternal Vaccine for Prevention of RSV in Infants: A Cost-Effectiveness Analysis for Mexico

Overview

Journal Vaccines (Basel)

Date 2025 Jan 24

PMID 39852856

Authors

Jose Luis Huerta

Robyn Kendall

Luka Ivkovic

Carlos Molina

Amy W Law

Diana Mendes

Affiliations

Soon will be listed here.

Abstract

Background/objectives: Respiratory syncytial virus (RSV) is a leading cause of respiratory infections in children. A novel RSVpreF vaccine for use among pregnant women for the prevention of RSV in infants is expected to be licensed in Mexico. Hence, the clinical and economic burden of RSV among infants in Mexico, with and without a year-round RSVpreF maternal vaccination program, was estimated.

Methods: A cohort model was developed to project clinical and economic outcomes of RSV from birth to 1 year of age for maternal vaccination and no intervention. Incremental cost-effectiveness ratios were calculated from direct cost outcomes, life years, and quality-adjusted life years (QALYs). The value per dose of the RSVpreF for which the program would be cost-effective was explored. Analyses were conducted from the healthcare system perspective, with direct costs (2024 Mexican Pesos [MXN]) and outcomes discounted at 5% annually; scenario and sensitivity analyses tested the robustness of model settings and inputs.

Results: Compared to no intervention, a year-round RSVpreF vaccine administered to 1891 M pregnant women would prevent 15,768 hospitalizations, 5505 emergency department cases, and 5505 physician office visits annually, averting MXN 1754 M in direct medical costs with an increase of 3402 life years or 3666 QALYs. The RSVpreF vaccine would be cost-saving up to MXN 1301/dose and cost-effective up to MXN 2105-MXN 3715/dose under an assumed cost-effectiveness threshold range of 1-3× the gross domestic product (GDP) per capita (MXN 247,310) per QALY gained.

Conclusions: Year-round RSVpreF maternal vaccination would substantially reduce RSV's clinical and economic burden among infants in Mexico and likely be a cost-effective program.

References

Gamino-Arroyo A, Moreno-Espinosa S, Llamosas-Gallardo B, Ortiz-Hernandez A, Guerrero M, Galindo-Fraga A . Epidemiology and clinical characteristics of respiratory syncytial virus infections among children and adults in Mexico. Influenza Other Respir Viruses. 2016; 11(1):48-56. PMC: 5155644. DOI: 10.1111/irv.12414. View

Fleming-Dutra K, Jones J, Roper L, Prill M, Ortega-Sanchez I, Moulia D . Use of the Pfizer Respiratory Syncytial Virus Vaccine During Pregnancy for the Prevention of Respiratory Syncytial Virus-Associated Lower Respiratory Tract Disease in Infants: Recommendations of the Advisory Committee on Immunization Practices -.... MMWR Morb Mortal Wkly Rep. 2023; 72(41):1115-1122. PMC: 10578951. DOI: 10.15585/mmwr.mm7241e1. View

Li Y, Wang X, Blau D, Caballero M, Feikin D, Gill C . Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis. Lancet. 2022; 399(10340):2047-2064. PMC: 7613574. DOI: 10.1016/S0140-6736(22)00478-0. View

Hansen C, Chaves S, Demont C, Viboud C . Mortality Associated With Influenza and Respiratory Syncytial Virus in the US, 1999-2018. JAMA Netw Open. 2022; 5(2):e220527. PMC: 8886548. DOI: 10.1001/jamanetworkopen.2022.0527. View

Simas C, Larson H, Paterson P . "Saint Google, now we have information!": a qualitative study on narratives of trust and attitudes towards maternal vaccination in Mexico City and Toluca. BMC Public Health. 2021; 21(1):1170. PMC: 8212502. DOI: 10.1186/s12889-021-11184-y. View

Simoes E, Center K, Tita A, Swanson K, Radley D, Houghton J . Prefusion F Protein-Based Respiratory Syncytial Virus Immunization in Pregnancy. N Engl J Med. 2022; 386(17):1615-1626. DOI: 10.1056/NEJMoa2106062. View

Jara J, Azziz-Baumgartner E, De Leon T, Luciani K, Brizuela Y, Estripeaut D . Costs associated with acute respiratory illness and select virus infections in hospitalized children, El Salvador and Panama, 2012-2013. J Infect. 2019; 79(2):108-114. DOI: 10.1016/j.jinf.2019.05.021. View

Hodgson D, Wilkins N, van Leeuwen E, Watson C, Crofts J, Flasche S . Protecting infants against RSV disease: an impact and cost-effectiveness comparison of long-acting monoclonal antibodies and maternal vaccination. Lancet Reg Health Eur. 2024; 38:100829. PMC: 10928299. DOI: 10.1016/j.lanepe.2023.100829. View

Simoes E, Pahud B, Madhi S, Kampmann B, Shittu E, Radley D . Efficacy, Safety, and Immunogenicity of the MATISSE (Maternal Immunization Study for Safety and Efficacy) Maternal Respiratory Syncytial Virus Prefusion F Protein Vaccine Trial. Obstet Gynecol. 2025; 145(2):157-167. PMC: 11731064. DOI: 10.1097/AOG.0000000000005816. View

10.

Vizcarra-Ugalde S, Rico-Hernandez M, Monjaras-Avila C, Bernal-Silva S, Garrocho-Rangel M, Ochoa-Perez U . Intensive Care Unit Admission and Death Rates of Infants Admitted With Respiratory Syncytial Virus Lower Respiratory Tract Infection in Mexico. Pediatr Infect Dis J. 2016; 35(11):1199-1203. DOI: 10.1097/INF.0000000000001262. View

11.

Mata-Moreno G, Bernal-Silva S, Garcia-Sepulveda C, Gonzalez-Ortiz A, Ochoa-Perez U, Medina-Serpa A . Population-based Influenza and Respiratory Syncytial Virus Hospitalizations and In-hospital Mortality Rates Among Mexican Children Less Than Five Years of Age. Pediatr Infect Dis J. 2024; 43(6):493-497. DOI: 10.1097/INF.0000000000004269. View

12.

Sartori A, de Soarez P, Fernandes E, Gryninger L, Viscondi J, Novaes H . Cost-effectiveness analysis of universal maternal immunization with tetanus-diphtheria-acellular pertussis (Tdap) vaccine in Brazil. Vaccine. 2016; 34(13):1531-1539. DOI: 10.1016/j.vaccine.2016.02.026. View

13.

Li X, Hodgson D, Flaig J, Kieffer A, Herring W, Beyhaghi H . Cost-Effectiveness of Respiratory Syncytial Virus Preventive Interventions in Children: A Model Comparison Study. Value Health. 2022; 26(4):508-518. DOI: 10.1016/j.jval.2022.11.014. View

14.

Shoukat A, Abdollahi E, Galvani A, Halperin S, Langley J, Moghadas S . Cost-effectiveness analysis of nirsevimab and maternal RSVpreF vaccine strategies for prevention of Respiratory Syncytial Virus disease among infants in Canada: a simulation study. Lancet Reg Health Am. 2023; 28:100629. PMC: 10663690. DOI: 10.1016/j.lana.2023.100629. View

15.

Kampmann B, Madhi S, Munjal I, Simoes E, Pahud B, Llapur C . Bivalent Prefusion F Vaccine in Pregnancy to Prevent RSV Illness in Infants. N Engl J Med. 2023; 388(16):1451-1464. DOI: 10.1056/NEJMoa2216480. View

16.

Hutton D, Prosser L, Rose A, Mercon K, Ortega-Sanchez I, Leidner A . Cost-Effectiveness of Nirsevimab for Respiratory Syncytial Virus in Infants and Young Children. Pediatrics. 2024; 154(6). DOI: 10.1542/peds.2024-066461. View

17.

Rha B, Curns A, Lively J, Campbell A, Englund J, Boom J . Respiratory Syncytial Virus-Associated Hospitalizations Among Young Children: 2015-2016. Pediatrics. 2020; 146(1). DOI: 10.1542/peds.2019-3611. View

18.

Gentile A, Lucion M, Juarez M, Areso M, Bakir J, Viegas M . Burden of Respiratory Syncytial Virus Disease and Mortality Risk Factors in Argentina: 18 Years of Active Surveillance in a Children's Hospital. Pediatr Infect Dis J. 2019; 38(6):589-594. DOI: 10.1097/INF.0000000000002271. View

19.

Cunningham S, Zar H . New Interventions to Prevent Respiratory Syncytial Virus Disease in Infants-Time for Equitable Global Access. Am J Respir Crit Care Med. 2023; 207(12):1556-1557. PMC: 10273123. DOI: 10.1164/rccm.202303-0568VP. View

20.

Wasserman M, Palacios M, Grajales A, BaezRevueltas F, Wilson M, McDade C . Modeling the sustained use of the 13-valent pneumococcal conjugate vaccine compared to switching to the 10-valent vaccine in Mexico. Hum Vaccin Immunother. 2018; 15(3):560-569. PMC: 6605727. DOI: 10.1080/21645515.2018.1516491. View